Capabilities by Region: Israel

Greenhill has significant advisory experience in Israel. Our Managing Directors and professionals have advised clients on transactions involving a number of leading companies in the region.

In 2019, in order to further strengthen our historical capabilities in Israel and enhance our cross-border offerings to clients, Greenhill entered into a cooperation agreement with Goren Capital Group, a leading investment banking firm based in Tel Aviv.  

Through the Goren Capital alliance, Greenhill is able to provide local insight to global clients interested in Israel, as well as provide global reach to clients in Israel who are looking abroad for opportunities.  

For more information on Goren Capital and the partnership with Greenhill’s advisory practice in Israel, please contact Samuel Gortler, Goren’s Executive Chairman, in Tel Aviv.

Below we highlight a few of the transactions on which we have advised in this region:

Recent Transactions

並べ替え

2016 年 06 月 20 日
$NA
Israel flag
被買収企業: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
買収企業: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

2016 年 06 月 28 日
$NA
Israel flag
被買収企業: 

US rights to an authorized generic version of Adderall XR

United States flag
買収企業: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

2016 年 10 月 05 日
$NA
Israel flag
被買収企業: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
買収企業: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

2016 年 11 月 24 日
$NA
Israel flag
被買収企業: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
買収企業: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

2016 年 11 月 23 日
$NA
Israel flag
被買収企業: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
買収企業: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

2016 年 06 月 16 日
$40 million
Israel flag
被買収企業: 

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
買収企業: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

2010 年 09 月 21 日
$234 million
Israel flag
被買収企業: 

Taro Pharmaceutical Industries

India flag
買収企業: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

2006 年 08 月 04 日
$290 million
United States flag
被買収企業: 

Republic Companies Group, Inc.

Israel flag
買収企業: 
Delek Capital Ltd.

Advised Republic Companies Group, Inc., a regional provider of personal and commercial property and casualty insurance products

2016 年 06 月 11 日
$350 million
Israel flag
被買収企業: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
買収企業: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

2016 年 06 月 21 日
$586 million
Israel flag
被買収企業: 

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
買収企業: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

2016 年 06 月 28 日
$652 million
Israel flag
被買収企業: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
買収企業: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

2016 年 10 月 05 日
$775 million
U.K., Ireland flags
被買収企業: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
買収企業: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

2018 年 05 月 07 日
$7.1 billion
Israel flag
被買収企業: 

Frutarom

United States flag
買収企業: 
International Flavors and Fragrances

Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition

2015 年 07 月 27 日
$40.5 billion
Ireland flag
被買収企業: 

Allergan Generics

Israel flag
買収企業: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

すべて表示